Araoz & Rueda acts for Dermapharm on €200m Euromed deal

Araoz & Rueda advised Dermapharm on the acquisition of the Spanish herbal extract manufacturer Euromed.

Dermapharm acquired Barcelona-based Euromed from US private equity fund The Riverside Company, which instructed Allen & Overy on the deal.

The transaction was valued at €200 million, according to Mergermarket.

Euromed is a manufacturer of herbal extracts for the pharmaceutical and cosmetic industries. In 2019, Euromed is expected to generate revenues of €70 million and earnings before interest, taxes, depreciation and amortization (EBITDA) of €20 million.

The Araoz & Rueda team was led by partner Alejandro Fernández de Araoz (pictured) and associate Vicente Paramio.

An Araoz & Rueda statement said: “The transaction is part of the growth plan of the German multinational to strengthen its international expansion, taking advantage of the knowledge of Euromed of the Spanish market.”

The financial advisers on the transaction were Rothschild, Fidentiis and Ferber & Co.